TRT and high hematocrit: what the evidence actually says

What did @leviathannutrition actually say?

The creator claims that even low-dose testosterone can raise red blood cell count, hemoglobin, and hematocrit in some patients, causing symptoms like excessive sleepiness and elevated cardiovascular risk. They call hematocrit elevation "the number one side effect that doctors noticed" on TRT, then pivot to promoting a product called Hemaflow, suggesting it controls hematocrit, hemoglobin, blood pressure, and clotting so patients can "stay on their TRT" without labs going out of range.

The core claim about polycythemia being a real TRT risk is grounded in real medicine. The supplement pitch attached to it is not.

Does the science back this up?

Yes, on the biology. No, on the supplement as a solution. Testosterone stimulates erythropoiesis, meaning it signals the bone marrow to produce more red blood cells. This is well-documented and dose-dependent, though individual variation is significant.

A 2010 meta-analysis by Calof et al. in the Journals of Gerontology found that testosterone therapy was associated with a statistically significant increase in hematocrit compared to placebo. The Testosterone Trials (Snyder et al., 2016, NEJM) also flagged hematocrit elevation as a measurable adverse effect across multiple outcome domains. Elevated hematocrit increases blood viscosity, which in theory raises thrombotic risk, though the clinical magnitude of that risk in otherwise healthy hypogonadal men remains debated. The claim that "falling asleep" while talking to someone is a symptom of thick blood is a reach. Fatigue and somnolence are nonspecific and not a recognized hallmark presentation of polycythemia in TRT patients.

What did they get wrong (or right)?

They got the mechanism broadly right. Testosterone raises hematocrit, and high hematocrit does increase cardiovascular risk. Credit where it's due.

But several things are off. First, calling it "the number one side effect" is not supported by the literature in a straightforward ranking. Injection site reactions, acne, testicular atrophy, and mood changes are also commonly reported. Polycythemia is significant, but framing it as definitively number one is an overstatement.

Second, the claim that a supplement like Hemaflow can "keep those levels from climbing too high" so labs stay in range is not supported by any clinical evidence presented, or any evidence this reviewer could find. The standard clinical interventions for elevated hematocrit on TRT are dose reduction, switching delivery method, or therapeutic phlebotomy. Suggesting a supplement can substitute for those interventions is misleading and potentially dangerous if it delays appropriate medical management.

Third, the sleepiness symptom framing is loose at best. Polycythemia vera can cause fatigue, but the image of someone falling asleep mid-conversation as a TRT hematocrit symptom is dramatized and not well-grounded clinically.

What should you actually know?

If you are on TRT, hematocrit monitoring is a legitimate and important part of follow-up care. Most clinical guidelines, including those from the Endocrine Society (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism), recommend checking hematocrit at baseline, then at 3 to 6 months, and annually thereafter. A hematocrit above 54 percent is generally considered a threshold for intervention.

The actual interventions with clinical backing are: dose reduction, switching from injections to transdermal formulations (which tend to produce smaller hematocrit increases), or therapeutic phlebotomy. No supplement has been validated in peer-reviewed trials as a hematocrit management tool for TRT-induced polycythemia.

• Do not rely on a supplement to manage out-of-range labs.
• If your hematocrit is climbing, tell your prescribing clinician before it becomes a problem.
• Regular bloodwork is not optional on TRT; it is the actual safety mechanism here.

The creator is right that this is a real issue worth talking about. The solution they offer is not the one the evidence supports.